[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
复制标题
DOI：
10.1371/journal.pone.0087629
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Hureaux J
中科院分区：
文献类型：
--
作者：
Hachemi M;Couturier O;Vervueren L;Fosse P;Lacœuille F;Urban T;Hureaux J
本前瞻性研究的目的是评价在厄洛替尼治疗开始后2周内进行的[18 F]FDG-PET/CT是否可以预测不能手术（IIIA至IV期）非小细胞肺癌患者治疗8周后的肿瘤缓解（根据RECIST 1.1标准定义）。在厄洛替尼治疗前（5±4天）和治疗后9±3天（早期PET）和60±6天（晚期PET），对12例患者进行了3次[18F]FDG-PET/CT扫描。根据RECIST 1.1标准进行常规评价，至少包括胸部CT（基线与治疗8周后）。将[18F]FDG摄取的变化与常规缓解、无进展生存期（PFS）和总生存期（OS）进行比较。通过使用ROC分析，早期PET预测代谢性非进展性疾病（mNP）的曲线下面积为0.86（95% CI，0.62至1.1; P = 0.04），截止值为最大标准摄取值（SUVmax）降低21.6%。 这正确分类了11/12例患者（7例为真正进展性疾病; 4例为真正非进展性疾病; 1例为假进展性疾病）。根据RECIST 1.1标准，治疗8周后的非进展性疾病在分类为mNP的患者中显著更常见（P = 0.01，Fisher精确检验）。 mNP患者的PFS（HR = 0.27; 95% CI，0.04 - 0.59; P<0.01）和OS（HR = 0.34; 95% CI，0.06 - 0.84; P = 0.03）延长。 后期PET分析提供了一致的结果。开始厄洛替尼治疗后2周内，可以通过[18 F]FDG-PET/CT扫描预测非小细胞肺癌患者的形态学缓解、PFS和OS生存期。
The aim of this prospective study was to evaluate whether [18F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in patients with inoperable (stage IIIA to IV) non-small cell lung cancer patients. Three [18F]FDG-PET/CT scans were acquired in 12 patients before (5±4 days) and after 9±3 days (early PET) and 60±6 days (late PET) of erlotinib therapy. Conventional evaluation, including at least chest CT (baseline versus after 8 weeks of treatment), was performed according to RECIST 1.1 criteria. Change in [18F]FDG uptake was compared with conventional response, progression-free survival (PFS), and overall survival (OS). By using ROC analysis, the Area Under the Curve for prediction of metabolic non-progressive disease (mNP) by early PET was 0.86 (95% CI, 0.62 to 1.1; P = 0.04) at a cut-off of 21.6% reduction in maximum Standardized Uptake Value (SUVmax). This correctly classified 11/12 patients (7 with true progressive disease; 4 with true non-progressive disease; 1 with false progressive disease). Non-progressive disease after 8 weeks of treatment according to RECIST 1.1 criteria was significantly more frequent in patients classified mNP (P = 0.01, Fisher's exact test). mNP patients showed prolonged PFS (HR = 0.27; 95% CI, 0.04 to 0.59; P<0.01) and OS (HR = 0.34; 95% CI, 0.06 to 0.84; P = 0.03). Late PET analysis provided concordant results. Morphologic response, PFS and OS survival in non-small cell lung cancer patients can be predicted by [18F]FDG-PET/CT scan within 2 weeks after starting erlotinib therapy.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
DOI：
10.2967/jnumed.111.095257
发表时间：
2011-11
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Benz MR;Herrmann K;Walter F;Garon EB;Reckamp KL;Figlin R;Phelps ME;Weber WA;Czernin J;Allen-Auerbach MS
通讯作者：
Allen-Auerbach MS
DOI：
10.1007/s00259-004-1533-x
发表时间：
2004-06-01
影响因子：
9.1
作者：
Biersack, HJ;Bender, H;Palmedo, H
通讯作者：
Palmedo, H
影响因子：
1.3
作者：
Messiou, Christina;Cook, Gary;de Souza, Nandita M.
通讯作者：
de Souza, Nandita M.